Rashes and Skin Irritations Summer heat, poison ivy, swimming in certain water, perspiration and other factors can cause skin irritations and rashes. Heat and Sweat Hot summer air and sweat can cause ...

Findings from the RAMP 201 trial showed a confirmed overall response rate of 44% (95% CI, 31-58).

The rainy weather may bring relief from the summer heat, but it can also cause trouble for your skin. From oily breakouts to itchy rashes and fungal infections, monsoon season can be tough on your ...

Whereas previously cumulative dosing has been advocated, it is now recommended that the duration and dose of isotretinoin should relate to the clinical response. [146] Most cases of acne ...

Five-year View The scope for the development of novel acne therapies appears promising. Research into acne pathogenesis has clearly demonstrated that acne is a T-cell-mediated condition, and with ...

Cobimetinib in ECD patients is associated with acneiform rashes, fatigue, and diarrhea, and rarely with thrombocytopenia, cytolysis, edema, and hypertension (111). Table 5 summarizes the topical and ...

Dr Chopra says if you suffer from allergies or frequently get ill with coughs and colds, you could have a weakened immune system thanks to poor gut health. Acne, eczema, and rashes Dr Chopra said ...

Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule, which has completed enrollment in a phase 2 clinical trial in metastatic colorectal ...

Presentation Title: A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies ...

Presentation Details: Presentation Title: A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from ...

Lutris Pharma's lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule, which has completed enrollment in a phase 2 clinical trial in metastatic colorectal ...